Mateon Therapeutics Inc., of South San Francisco, presented final data from the phase II OX4218 study in patients with neuroendocrine tumors, or NETs, at the Gastrointestinal Cancers Symposium in San Francisco. In OX4218, patients were treated with vascular-disrupting agent combretastatin A4-phosphate (CA4P) 60 mg/m2 on days one, eight and 15 of a 21-day cycle for three cycles. A total of 18 patients were enrolled. Data showed one patient (6 percent) experienced significant symptomatic improvement as measured by ECOG Status and had a partial response per investigator-assessed RECIST, and an additional seven patients (39 percent) had stable disease.